Riskpilot← Back to searchSign inGet full accessGLAXOSMITHKLINE PHARMA A/S
A/SActiveCVR 27394019Delta Park 37Wholesale of pharmaceutical and medical goods · NACE 4646Est. 196883 employeeshttps://www.gsk.com
Revenue 2024
DKK 548,5M
+16% vs 2023
EBITDA margin
3.1%
+5% vs 2023
Equity ratio
38.5%
Financial strength
Net profit 2024
DKK 12,2M
+2% vs 2023
| Revenue | DKK 548,5M | +16% |
| EBITDA | DKK 17M | +5% |
| Net profit | DKK 12,2M | +2% |
| Total assets | DKK 99,1M | -16% |
| Equity | DKK 38,1M | +1% |
| Employees | 83 | — |
Legal name
GLAXOSMITHKLINE PHARMA A/S
CVR number
27394019
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11. december 1968
Share capital
DKK 10.000.000
Employees
83 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem, af to medlemmer af bestyrelsen i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive handel
Address
Delta Park 37
Phone
+4536359100
Email
dk-info@gsk.com
Website
https://www.gsk.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 364.257 | 371.489 | 338.938 | 366.477 | 426.868 | 413.846 | 417.448 | 441.702 | 445.873 | 440.283 | 474.477 | 548.470 |
| Staff expenses | -71.795 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -103.410 | -103.673 | -117.575 |
| EBITDA | 25.000 | 17.309 | 5.653 | 15 | 12.786 | 23.568 | -11.714 | 14.630 | -11.001 | 15.851 | 16.108 | 16.959 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1.851 | -364 | -364 |
| EBIT | 25.000 | 17.309 | 5.653 | 15 | 12.786 | 23.568 | -11.714 | 14.630 | -11.001 | 14.000 | 15.744 | 16.595 |
| Net financials | 201 | -449 | -98 | -1.587 | -43 | -526 | -261 | -79 | 37 | 10 | -281 | -330 |
| Profit before tax | 18.759 | 16.860 | 5.555 | 3.027 | 12.743 | 23.042 | 14.722 | 14.551 | 14.309 | 14.341 | 15.463 | 16.265 |
| Tax | 4.287 | 5.096 | 1.890 | 1.155 | 3.146 | 5.519 | 3.626 | 2.280 | 5.325 | 3.273 | 3.460 | 4.025 |
| Net profit | 14.472 | 11.764 | 3.665 | 1.872 | 9.597 | 17.523 | 11.096 | 12.271 | 8.984 | 11.068 | 12.003 | 12.240 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 266.969 | 229.869 | 235.844 | 331.952 | 192.045 | 231.746 | 173.563 | 160.064 | 137.489 | 115.803 | 117.324 | 99.094 |
| Equity | 146.906 | 144.270 | 147.935 | 25.807 | 35.404 | 39.427 | 35.523 | 37.794 | 34.778 | 36.946 | 37.889 | 38.129 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 112.862 | 78.932 | 81.785 | 300.548 | 152.108 | 187.928 | 133.899 | 121.292 | 102.026 | 78.647 | 79.435 | 60.965 |
| Total debt | 112.862 | 78.932 | 81.785 | 300.548 | 152.108 | 187.928 | 133.899 | 121.292 | 102.026 | 78.647 | 79.435 | 60.965 |
EBITDA margin
3.1%
This company
15.8%
Market median
-80% vs market
20132024
Equity ratio
38.5%
This company
38.2%
Market median
+1% vs market
20132024
Return on equity
32.1%
This company
18.4%
Market median
+74% vs market
20132024
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20132024
Asset turnover
5.53×
This company
1.12×
Market median
+394% vs market
20132024
Debt / equity
1.60×
This company
0.62×
Market median
-158% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DM Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
FJ Management | Management | 2000 | — | — |
JM Chief Executive Officer | Chief Executive Officer | 2007 | — | — |
MJ Management | Management | 2001 | — | — |
DM Management | Management | 2023 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2004 | — | — |
CC Management | Management | 1968 | — | — |
JL Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
SF Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
MF Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
DM Management | Management | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2003 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 1968 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 1968 | — | — | |
| Chairman | 2013 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2001 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2018 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 1998 | — | — | |
| Board of Directors | 2010 | — | — | |
| Chairman | 2008 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 1968 | — | — | |
| Chairman | 2005 | — | — | |
| Chairman | 2017 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GLAXOSMITHKLINE PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| David Mattheus Fredericus Rademakers | Chief Executive Officer | 0 companies |
| Frederik Jan van Snippenberg | Management | 0 companies |
| Julie Maree Edwards | Chief Executive Officer | 0 companies |
| Michael John Crow | Management | 0 companies |
| Dominika M Wiktor-Brown | Management | 0 companies |
| Simon Anthony Jose | Chief Executive Officer | 0 companies |
| Carl Christian Juhlsgaard Jepsen | Management | 0 companies |
| Judith Lynne Stewart | Chief Executive Officer | 0 companies |
| Saskia Fontein | Chief Executive Officer | 0 companies |
| Michael Francis Connell | Chief Executive Officer | 0 companies |
| Diederik Maarten Eijsvogel | Management | 0 companies |
| Geradus Wilhelmus Maria van Odijk | Chairman | 0 companies |
| Anne Margaret Belcher | Chairman | 0 companies |
| Simon Cresey Davidson | Chairman | 0 companies |
| Joshua Rhys Williams | Board of Directors | 0 companies |
| Angus Robertson | Chairman | 0 companies |
| Birgit Yvonne Reimann | Chairman | 0 companies |
| Luciano Alves de Andrade | Chairman | 0 companies |
| Douglas Malcolm Hurt | Chairman | 0 companies |
| Hemal Depan Malde | Board of Directors | 0 companies |
| Neale Andrew Belson | Chairman | 0 companies |
| Daniël Gijbels | Chairman | 0 companies |
| Helle Ann Hellberg | Board of Directors | 0 companies |
| Siero Keimpe Roosjen | Chairman | 0 companies |
| Ole Jensen-Dahm | Board of Directors | 0 companies |
| Frederik Jan van Snippenberg | Chairman | 0 companies |
| Patrick Gerard Connor | Chairman | 0 companies |
| Helge Hassel | Board of Directors | 0 companies |
| David Simon Redfern | Chairman | 0 companies |
| Josephine Yang Comiskey | Chairman | 0 companies |
| Georgios Katzourakis | Chairman | 0 companies |
| Hans Hedegaard | Board of Directors | 0 companies |
| Tetiana Luczkiw | Board of Directors | 0 companies |